ComMedX

AI and Computational-Driven Innovation

Rapid Identification and Optimization of Lead Compounds
Meeting the Needs for Small Molecule Innovative Drug Development from Concept to Reality

is a platform company focused on computational chemistry-driven drug research and development.

Utilizing leading global technologies such as large-scale virtual screening based on protein three-dimensional structures and artificial intelligence, we provide early-stage development services for small molecule innovative drugs to pharmaceutical companies and research institutions worldwide. Our services rapidly identify and optimize lead compounds, addressing the urgent needs for small molecule drug development from concept to reality.

Our core technology team, hailing from the University of California, San Francisco and the Beijing Institute of Life Sciences, aims to industrialize scientific research findings by integrating cutting-edge technologies from biology, chemistry, pharmacy, and computer science, thereby accelerating the development of original innovative drugs.

Integrated AI Algorithms, Data, and Physics for Smart Discovery of Small Molecule Drugs

The MedxIntegra platform integrates advanced AI algorithms, physical models, and cheminformatics data to drive the rational discovery and design of innovative drugs, efficiently exploring chemical space and accelerating the drug development process.

One-Stop Drug Development Services Combining Computational Analysis, Chemical Synthesis, and Biological Testing

Leveraging the smart computing, chemical synthesis, and biological testing capabilities of the MedxIntegra platform, Commedison offers high-quality drug development CRO services to global partners, helping clients discover and optimize the best compounds.